Kellie Rademacher and Hetty Lima from the Payer Access Solutions team provide guidance into evaluation and valuation in the orphan drug space, currently one of the most active areas of drug development. With the FDA working to streamline the approval process for innovative orphan drugs, there is much promise on the horizon for providing breakthrough treatments, but also unique challenges with payers with regard to pricing and value.

Lee Goldberg from our Product Management team shares key takeaways from the recently conducted Rapid Pulse survey—our proprietary high-speed survey and analysis service providing pharmaceutical marketers with feedback from market access decision makers—on payer perceptions of PIE.

Maureen Hennessey from our Quality and Population Health Solutions team provides an overview of MACRA, Medicare’s evolution toward value-based clinical reimbursement. Maureen breaks down the separate tracks of participation for providers and highlights some guidelines for demonstrating value that manufacturers will need to demonstrate.

Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny—all while trying to satisfy investors. Dominic Galante, chief medical officer with our Quality and Population Health Solutions team, makes the case that the patient perspective on value has never been more important.

Recently, in conjunction with MM&M magazine, Precision Promotional Effectiveness hosted a special live webinar, Pull-through Breakthrough: How your peers are driving double-digit gains now and in ’18. Led by Promotional Effectiveness’ Bruce Leavitt, executive vice president and managing partner, and Ashwin Athri, senior vice president, the webinar is now available on-demand. Read on to learn some key insights from the webinar and get the link to view it at your convenience.